SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH M impact

Sacituzumab Tirumotecan Cut Death Risk 32% in Endometrial Cancer Patients

Sacituzumab tirumotecan reduced the risk of disease progression or death by 41% versus chemotherapy in certain patients with advanced or recurrent endometrial cancer.

MRK

Story updates

03:30:38 PM UTC
SquawkNews
Merck reported Phase 3 TroFuse-005 data showing sacituzumab tirumotecan cut risk of death 32% (HR 0.68) and progression/death 41% (HR 0.59) vs chemo in previously treated endometrial cancer; FDA accepted priority review with a PDUFA target of June 15, 2027.Material DetailsContext by AI AnalystThis…

Related stories